Literature DB >> 9029015

In vivo coagulation activation following infusion of highly purified factor XI concentrate.

E M Richards1, M M Makris, P Cooper, F E Preston.   

Abstract

The use of factor XI concentrates has been associated with thrombosis. Plasma markers of coagulation activation were measured before and 30, 60, 120 and 240 min after six infusions of the BPL factor XI concentrate. Five studies were completed before surgical intervention, one was undertaken in a patient with an intracerebral haemorrhage. Significant elevation of levels of fibrinopeptide A (FpA) (P < 0.05) and thrombin-antithrombin (TAT) were demonstrated following six infusions and prothrombin fragment F1.2 following four. Levels of all three markers had risen 60 min following concentrate administration and FpA levels remained elevated throughout the study period. Levels of D-dimer rose in four patients at 240 min. These results indicate significant thrombin generation by 60 min and subsequent plasmin generation consistent with coagulation activation by the factor XI concentrate. The greatest elevation of activation markers was seen in those subjects with pre-existing coagulation activation. We advise caution in the use of these products and awareness of the risks in patients who may already have activated coagulation states.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9029015     DOI: 10.1046/j.1365-2141.1997.d01-2015.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  Evidence for factor IX-independent roles for factor XIa in blood coagulation.

Authors:  A Matafonov; Q Cheng; Y Geng; I M Verhamme; O Umunakwe; E I Tucker; M-F Sun; V Serebrov; A Gruber; D Gailani
Journal:  J Thromb Haemost       Date:  2013-12       Impact factor: 5.824

2.  Synergy Between Tissue Factor and Exogenous Factor XIa in Initiating Coagulation.

Authors:  Karin Leiderman; William C Chang; Mikhail Ovanesov; Aaron L Fogelson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-10-27       Impact factor: 8.311

3.  Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study.

Authors:  F Bauduer; E de Raucourt; C Boyer-Neumann; M Trossaert; P Beurrier; A Faradji; J Peynet; J-Y Borg; P Chamouni; C Chatelanaz; C Henriet; F Bridey; J Goudemand
Journal:  Haemophilia       Date:  2015-03-26       Impact factor: 4.287

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.